Hanson wade has taken the decision to cancel this meeting.

Please do accept our apologies for any inconvenience or disappointment this will cause.
Please register your interest here if you would like updates on the meeting or topic.

Accelerate the Development of Safe & Effective, Novel Drugs, Sequences & Combinatorial Therapies for Prostate Cancer

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics to accelerate the clinical development of safe and effective therapies to treat prostate cancer.

With sessions on both early and advanced stages of prostate cancer (Non-Metastatic Castrate-Resistant Prostate Cancer -nmCRPC- and Metastatic Castrate-Resistant Prostate Cancer -mCRPC-), this is a conversation not to miss!

Brought directly to your home office, network with 80+ prostate cancer experts, with the likes of Amgen, Bristol-Myers Squibb, Novartis and Noxopharm. We will discuss how to tackle specific and applied drug development challenges limiting effective therapies. This includes navigating cancer heterogeneity, determining efficacy and clinically meaningful endpoints along with overcoming drug resistance

Whether you are developing SARDs, PARP inhibitors, or targeting PSMAs, ADCs, or bispecific antibodies for the treatment of prostate cancer, attend this meeting to accelerate the understanding of prostate cancer biology, discuss novel, cutting edge targeted therapies, and overcome common challenges with the current clinical treatment landscape for prostate cancer.

Among The Expert Speaker Faculty

Hear Why Our Attendees Are Excited About Joining This Summit:

"This meeting, which is well-timed, will discuss the cutting-edge prostate cancer drugs that will potentially advance to the clinic in the near future"

Professor, Department of Medicine & Director of Center for Cancer Drug Discovery, UTHSC

"A forum such as this which showcases the biotechnology behind the latest safe and efficacious potential treatments for mCRPC cancer is of global importance"

Chief Executive Officer & Founder, Noxopharm